Dennise Martinez
Associate
Dennise Martinez is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where her practice focuses primarily on mergers and acquisitions. She advises both public and private clients in mergers, tender offers, asset acquisitions, stock purchases, and other strategic corporate transactions.
Prior to attending law school, Dennise taught high school math in southern Texas through Teach for America.
Experience
Dennise Martinez is an associate in the San Francisco office of Wilson Sonsini Goodrich & Rosati, where her practice focuses primarily on mergers and acquisitions. She advises both public and private clients in mergers, tender offers, asset acquisitions, stock purchases, and other strategic corporate transactions.
Prior to attending law school, Dennise taught high school math in southern Texas through Teach for America.
Education
- J.D., UC Berkeley School of Law, 2016Business Law Certificate; Senior Supervising Editor, California Law Review; Co-Editor-in-Chief, Berkeley Business Law Journal; Recipient, American Jurisprudence Award
- B.B.A., Accountancy, University of Notre Dame, 2011Cum Laude
Admissions
- State Bar of California
Credentials
Education
- J.D., UC Berkeley School of Law, 2016Business Law Certificate; Senior Supervising Editor, California Law Review; Co-Editor-in-Chief, Berkeley Business Law Journal; Recipient, American Jurisprudence Award
- B.B.A., Accountancy, University of Notre Dame, 2011Cum Laude
Admissions
- State Bar of California
Select Matters
- Twitter in its $44 billion announced sale to entities affiliated with Elon Musk
- Alteryx in its $4.4 billion announced sale to Insight and Clearlake
- Poly in its $3.3 billion announced sale to HP
- Momentive Global in its proposed, but terminated, $4.1 billion all-stock acquisition by Zendesk
- Woodward in its $6.4 billion announced merger of equals with Hexcel
- Pacific Biosciences of California in its proposed, but terminated, $1.2 billion acquisition by Illumina
- Gainsight in its $1.1 billion announced sale to Vista Equity Partners
- Lumentum Holdings in its $750 million acquisition of Cloud Light Technology Limited
- Pacific Biosciences of California in its acquisitions of Omniome and Circulomics
- LinkedIn Corporation in its acquisition of Drawbridge
- GoFundMe in its acquisition of Classy
- Stripe in its acquisition of Bouncer
- Udemy in its acquisition of CorpU
- Box in its acquisition of multiple companies
Matters
Select Matters
- Twitter in its $44 billion announced sale to entities affiliated with Elon Musk
- Alteryx in its $4.4 billion announced sale to Insight and Clearlake
- Poly in its $3.3 billion announced sale to HP
- Momentive Global in its proposed, but terminated, $4.1 billion all-stock acquisition by Zendesk
- Woodward in its $6.4 billion announced merger of equals with Hexcel
- Pacific Biosciences of California in its proposed, but terminated, $1.2 billion acquisition by Illumina
- Gainsight in its $1.1 billion announced sale to Vista Equity Partners
- Lumentum Holdings in its $750 million acquisition of Cloud Light Technology Limited
- Pacific Biosciences of California in its acquisitions of Omniome and Circulomics
- LinkedIn Corporation in its acquisition of Drawbridge
- GoFundMe in its acquisition of Classy
- Stripe in its acquisition of Bouncer
- Udemy in its acquisition of CorpU
- Box in its acquisition of multiple companies
Focus Areas
Recent Insights
Client Highlights
Wilson Sonsini Advises Fluent BioSciences on Acquisition by Illumina
On July 9, 2024, Illumina, Inc., a global leader in DNA sequencing and array-based technologies, announced that it has acquired Fluent BioSciences (Fluent), developer of an emerging and highly differentiated single-cell technology. Wilson Sonsini Goodrich & Rosati advised Fluent on the transaction.
Learn More
Client Highlights
Firm Advises Silk Road Medical on $1.26 Billion Acquisition by Boston Scientific
On June 18, 2024, Silk Road Medical announced that it entered into a definitive agreement to be acquired by Boston Scientific Corporation for a purchase price of $27.50 per share, reflecting an aggregate equity value of approximately $1.26 billion. Silk Road Medical is a medical device company that has developed an innovative platform of products to prevent stroke in patients with carotid artery disease through a minimally invasive procedure called transcarotid artery revascularization (TCAR). Wilson Sonsini Goodrich & Rosati advised Silk Road Medical on the transaction.
Learn More
- Privacy Policy
- Terms of Use
- Accessibility
Copyright © 2024 Wilson Sonsini Goodrich & Rosati. All Rights Reserved.